Clarius Group LLC Buys 64 Shares of Illumina, Inc. (NASDAQ:ILMN)

Clarius Group LLC increased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 6.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,039 shares of the life sciences company’s stock after purchasing an additional 64 shares during the quarter. Clarius Group LLC’s holdings in Illumina were worth $385,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. Marshall Wace North America L.P. acquired a new stake in shares of Illumina in the 4th quarter worth about $1,497,000. Alliancebernstein L.P. raised its holdings in shares of Illumina by 78.9% in the 4th quarter. Alliancebernstein L.P. now owns 1,881,507 shares of the life sciences company’s stock worth $624,171,000 after acquiring an additional 829,865 shares during the last quarter. CSat Investment Advisory L.P. raised its holdings in shares of Illumina by 34.4% in the 4th quarter. CSat Investment Advisory L.P. now owns 500 shares of the life sciences company’s stock worth $166,000 after acquiring an additional 128 shares during the last quarter. Banco Bilbao Vizcaya Argentaria S.A. acquired a new stake in shares of Illumina in the 4th quarter worth about $608,000. Finally, Alberta Investment Management Corp raised its holdings in shares of Illumina by 12.9% in the 4th quarter. Alberta Investment Management Corp now owns 53,741 shares of the life sciences company’s stock worth $17,828,000 after acquiring an additional 6,141 shares during the last quarter. 89.88% of the stock is currently owned by institutional investors.

In other Illumina news, CFO Sam Samad sold 249 shares of the stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $292.54, for a total value of $72,842.46. Following the sale, the chief financial officer now directly owns 9,645 shares in the company, valued at approximately $2,821,548.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Phillip G. Febbo sold 173 shares of the stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $300.00, for a total transaction of $51,900.00. Following the completion of the sale, the senior vice president now owns 2,490 shares in the company, valued at $747,000. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 36,307 shares of company stock valued at $12,147,480. 0.38% of the stock is owned by insiders.

ILMN opened at $369.87 on Thursday. The company has a 50 day moving average of $360.16 and a 200 day moving average of $313.37. The company has a market cap of $54.70 billion, a PE ratio of 58.25, a price-to-earnings-growth ratio of 5.50 and a beta of 1.00. Illumina, Inc. has a 12 month low of $196.78 and a 12 month high of $384.21. The company has a current ratio of 4.10, a quick ratio of 3.74 and a debt-to-equity ratio of 0.29.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.64 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.25 by $0.39. The company had revenue of $859.00 million during the quarter, compared to the consensus estimate of $857.92 million. Illumina had a net margin of 26.48% and a return on equity of 21.78%. Illumina’s revenue for the quarter was up 1.5% on a year-over-year basis. During the same period last year, the firm earned $1.60 EPS. Research analysts forecast that Illumina, Inc. will post 6.15 earnings per share for the current fiscal year.

A number of equities research analysts recently weighed in on the stock. Stifel Nicolaus upped their target price on shares of Illumina from $298.00 to $325.00 and gave the stock a “buy” rating in a report on Friday, May 1st. Piper Sandler decreased their price objective on shares of Illumina from $370.00 to $356.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Guggenheim lowered shares of Illumina from a “buy” rating to a “neutral” rating in a research note on Tuesday. JPMorgan Chase & Co. increased their price objective on shares of Illumina from $340.00 to $390.00 and gave the company an “overweight” rating in a research note on Thursday, July 2nd. Finally, Wells Fargo & Co increased their price objective on shares of Illumina from $245.00 to $290.00 and gave the company an “underweight” rating in a research note on Friday, May 1st. Three analysts have rated the stock with a sell rating, six have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $335.44.

Illumina Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Read More: Profit Margin

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.